Myelodysplastic Syndrome Global Clinical Trials Review, H2, 2015
Summary
GlobalDatas clinical trial report, “Myelodysplastic Syndrome Global Clinical Trials Review, H2, 2015 provides an overview of Myelodysplastic Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Myelodysplastic Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Myelodysplastic Syndrome Therapeutics Clinical Trials 28
Prominent Drugs 30
Latest Clinical Trials News on Myelodysplastic Syndrome 31
Nov 24, 2015: CTI BioPharma Announces United Kingdom National Cancer Research Institute AML Cooperative Group Advances Tosedostat to Next Stage of "Pick-a-Winner" LI-1 Trial for Older Patients with AML or High-Risk MDS 31
Nov 12, 2015: INNATE PHARMA: New combination trial with lirilumab in hemato-oncology 31
Nov 09, 2015: TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 57th Annual American Society of Hematology Annual Meeting 32
Nov 05, 2015: MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome 32
Nov 05, 2015: Onconova Announces Data Presentation From Phase 2 Combination Trial of Oral Rigosertib and Azacitidine at the 2015 ASH Annual Meeting 33
Nov 05, 2015: Geron Announces Presentations at American Society of Hematology Annual Meeting 33
Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event 34
Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia 34
Clinical Trial Profile Snapshots 36
Appendix 1244
Abbreviations 1244
Definitions 1244
Research Methodology 1245
Secondary Research 1245
About GlobalData 1246
Contact Us 1246
Disclaimer 1246
Source 1247
List Of Tables
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Region, 2015* 6
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Myelodysplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Myelodysplastic Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Myelodysplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Myelodysplastic Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 13
Myelodysplastic Syndrome Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 14
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2015* 15
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2015* 18
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Myelodysplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 29
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 30
List Of Figures
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Myelodysplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Myelodysplastic Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Myelodysplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Myelodysplastic Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 13
Myelodysplastic Syndrome Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 14
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2015* 15
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2015* 18
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Myelodysplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 26
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 30
GlobalData Methodology 1245
